4-溴-2-甲氧基-1,1'-联苯 | 227305-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-甲氧基-1,1'-联苯
• 英文名称: 4-bromo-2-methoxy-1,1'-biphenyl
• 英文别名: 4-Bromo-2-methoxylbiphenyl；4-Bromo-2-methoxybiphenyl；4-bromo-2-methoxy-1-phenylbenzene
• CAS: 227305-07-9
• 化学式: C₁₃H₁₁BrO
• 分子量: 263.134
• InChiKey: ZREIJSSRWLYNDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-溴-2-甲氧基-1,1'-联苯 、 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1R)-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)hex-5-enoate 在 Pd(OAc)2[P(2-tolyl)3]2 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (Stromelysin-1)

  摘要：

  Structure-activity relationships are described for a series of succinyl hydroxamic acids 4a-o as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1' and P3' groups gave compound 4j (MMP-3 IC50 = 5.9nM) which was >140-fold less potent against MMP-1 (IC50 = 51,000nM), MMP-2 (IC50=1790nM), MMP-9 (IC50 = 840 nM) and MMP-14 (IC50 = 1900 nM). (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00720-4
• 作为产物：
  描述：

  亚硝酸正戊酯 、 4-溴-2-甲氧基苯胺 以 乙酸乙酯 、 苯 为溶剂， 生成 4-溴-2-甲氧基-1,1'-联苯
  参考文献：
  名称：

  US6387931

  摘要：

  公开号：

文献信息

• Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors
  申请人：Warner-Lambert Company

  公开号：US06495568B1

  公开（公告）日：2002-12-17

  Compounds of formula (I): or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line represents an optional bond; A is C or CH; B is CH2, O or absent; R1 and R2 are each independently selected from hydrogen, C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group which optionally incorporates a heteroatom linkage selected from O, SO, SO2 and NR6 or which is optionally benzo-fused; R3 is hydrogen, halo, R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl; R7 is an optionally substituted monocyclic or bicyclic ring system; m is 1 or 2; and n is 0, 1 or 2; with the proviso that B is not O when A is C; are MMP inhibitors useful in the treatment of, inter alia, tissue ulceration, wound repair and skin diseases.

  化合物的式子(I)：或其药学上或兽医学上可接受的盐，或这两个实体的药学上或兽医学上可接受的溶剂化物，其中断线代表可选键；A为C或CH；B为CH2、O或不存在；R1和R2各自独立地选自氢、C1至C6烷基，可选地被C1至C4烷氧基或苯基取代，以及C1至C6烯基；或与它们所连接的碳原子一起形成C3至C6环烷基，该环烷基可选地包括从O、SO、SO2和NR6中选择的杂原子键合或可选地与苯融合；R3为氢、卤素、R7或OR7；R4为氢、C1至C4烷基、C1至C4烷氧基、三氟甲基或卤素；R6为氢或C1至C4烷基；R7为可选取代的单环或双环环系统；m为1或2；n为0、1或2；但当A为C时，B不为O；这些MMP抑制剂在治疗组织溃疡、伤口修复和皮肤疾病等方面非常有用。
• HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1036062B1

  公开（公告）日：2004-01-02
• US6495568B1
  申请人：——

  公开号：US6495568B1

  公开（公告）日：2002-12-17
• US6387931
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (Stromelysin-1)
  作者：M.Jonathan Fray、RogerP Dickinson

  DOI：10.1016/s0960-894x(00)00720-4

  日期：2001.2

  Structure-activity relationships are described for a series of succinyl hydroxamic acids 4a-o as potent and selective inhibitors of matrix metalloprotease-3 (stromelysin-1). Optimisation of P1' and P3' groups gave compound 4j (MMP-3 IC50 = 5.9nM) which was >140-fold less potent against MMP-1 (IC50 = 51,000nM), MMP-2 (IC50=1790nM), MMP-9 (IC50 = 840 nM) and MMP-14 (IC50 = 1900 nM). (C) 2001 Elsevier Science Ltd. All rights reserved.